Physician profile
David Boyd Cox
NPI 1831351303
$599.51
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.26 · 2020: $51.39 · 2021: $309 · 2022: $147 · 2023: $57.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $179.47 | 2021-2022 | |
| Orthogenrx INC. | $51.39 | 2020 | |
| Janssen Pharmaceuticals, INC | $50.63 | 2021 | |
| Novo Nordisk INC | $41.22 | 2021 | |
| Dexcom, INC. | $38.63 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $35.26 | 2019 | |
| Amgen INC. | $33.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $30.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.10 | 2021-2022 | |
| Integra Lifesciences Corporation | $23.57 | 2023 | Tcc-Ez |
| Merck Sharp & Dohme LLC | $19.63 | 2021 | |
| Lilly USA, LLC | $19.28 | 2023 | Taltz |
| Pfizer INC. | $19.19 | 2022 | |
| Ucb, INC. | $15.84 | 2022 | |
| Amarin Pharma, INC. | $14.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.